LWANC
EDIT icon

Laurel Wealth Advisors (North Carolina)’s Editas Medicine EDIT Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500
Closed -$6K – 563
2022
Q2 		$6K Buy
500
+409
+449% +$5.48K ﹤0.01% 423
2022
Q1 		$2K Hold
91
– – ﹤0.01% 578
2021
Q4 		$2K Hold
91
– – ﹤0.01% 580
2021
Q3 		$4K Sell
91
-250
-73% -$13.7K ﹤0.01% 505
2021
Q2 		$19K Buy
+341
New +$12.6K ﹤0.01% 382

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s EDIT Position: Q3 2022 in Review

Laurel Wealth Advisors (North Carolina) sold out of Editas Medicine (EDIT) in Q3 2022, closing a stake of 500 shares — an estimated $6K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in EDIT in Q2 2021 and held it in 5 quarters. The position peaked at $19K in Q2 2021. 264 funds tracked by Wall St. Rank hold EDIT as of Q3 2022.

  • Laurel Wealth Advisors (North Carolina) reported no remaining Editas Medicine position as of Q3 2022 after selling out during the quarter.
  • Laurel Wealth Advisors (North Carolina) sold 500 Editas Medicine shares in Q3 2022, an estimated $6K.
  • Laurel Wealth Advisors (North Carolina) first reported a position in Editas Medicine in Q2 2021 and held it in 5 quarters.
  • Laurel Wealth Advisors (North Carolina)'s Editas Medicine position peaked at $19K in Q2 2021.
  • 264 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2022.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q3 2022, filed 15 Nov 2022.